Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study

Table 3 Multiple Cox regression analysis of AGR in patients with advanced NSCLC treated with anlotinib

Exposure	Crude model	Minimally adjusted model	Fully adjusted model
Exposure	Hazard ratio (95% CIs), p-value	Hazard ratio (95% CIs), p-value	Hazard ratio (95% CIs), p-value
AGR	0.47 (0.26, 0.84) 0.0105	0.53 (0.29, 0.96) 0.0365	0.40 (0.18, 0.88) 0.0230
AGR (tertiles)
Low	Ref	Ref	Ref
Middle	0.58 (0.36, 0.95) 0.0293	0.58 (0.35, 0.96) 0.0332	0.65 (0.36, 1.16) 0.1410
High	0.52 (0.32, 0.84) 0.0080	0.55 (0.33, 0.91) 0.0187	0.49 (0.26, 0.92) 0.0273
p for trend	0.0073	0.0164	0.0277

Crude model adjusted for: None
Minimally adjusted model adjusted for: Age; Gender; Never smoker
Fully adjusted model adjusted for: Age, years; Gender; Never smoker; Hypertension; ALK rearrangement; EGFR mutation; Histology; Tumor stage; ECOG PS score; Number of metastases; Number of previous treatment lines; Number of previous chemotherapy lines; Previous targeted therapy; Previous radiotherapy; Previous immunotherapy; Anlotinib monotherapy; Leukocyte; Neutrophil; Lymphocyte; Platelets. Restricted cubic spline was applied

ISSN: 1471-2466